Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 210

1.

Effect of IRAK-M on Airway Inflammation Induced by Cigarette Smoking.

Gong H, Liu T, Chen W, Zhou W, Gao J.

Mediators Inflamm. 2017;2017:6506953. doi: 10.1155/2017/6506953. Epub 2017 Aug 29.

2.

Prevention of Exacerbations in Chronic Obstructive Pulmonary Disease: Knowns and Unknowns.

Agustí A, Calverley PM, Decramer M, Stockley RA, Wedzicha JA.

Chronic Obstr Pulm Dis. 2014 Sep 25;1(2):166-184. doi: 10.15326/jcopdf.1.2.2014.0134. Review.

3.

Sputum mucin 1 is increased during the acute phase of chronic obstructive pulmonary disease exacerbation.

Zheng Z, Qi Y, Xu X, Jiang H, Li Z, Yang Q, Zhang C, Zhang K, Chen R, Wang J, Lu W.

J Thorac Dis. 2017 Jul;9(7):1873-1882. doi: 10.21037/jtd.2017.06.63.

4.

A multi-center randomized, controlled, open-label trial evaluating the effects of eosinophil-guided corticosteroid-sparing therapy in hospitalised patients with COPD exacerbations - The CORTICO steroid reduction in COPD (CORTICO-COP) study protocol.

Sivapalan P, Moberg M, Eklöf J, Janner J, Vestbo J, Laub RR, Browatzki A, Armbruster K, Wilcke JT, Seersholm N, Weinreich UM, Titlestad IL, Andreassen HF, Ulrik CS, Bødtger U, Nielsen TL, Hansen EF, Jensen JUS.

BMC Pulm Med. 2017 Aug 15;17(1):114. doi: 10.1186/s12890-017-0458-7.

5.

Epidemiology and impact of chronic bronchitis in chronic obstructive pulmonary disease.

Lahousse L, Seys LJM, Joos GF, Franco OH, Stricker BH, Brusselle GG.

Eur Respir J. 2017 Aug 10;50(2). pii: 1602470. doi: 10.1183/13993003.02470-2016. Print 2017 Aug.

6.

A randomised, placebo-controlled trial of anti-interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease.

Calverley PMA, Sethi S, Dawson M, Ward CK, Finch DK, Penney M, Newbold P, van der Merwe R.

Respir Res. 2017 Aug 9;18(1):153. doi: 10.1186/s12931-017-0633-7.

7.

Immunogenicity of Nontypeable Haemophilus influenzae Outer Membrane Vesicles and Protective Ability in the Chinchilla Model of Otitis Media.

Winter LE, Barenkamp SJ.

Clin Vaccine Immunol. 2017 Oct 5;24(10). pii: e00138-17. doi: 10.1128/CVI.00138-17. Print 2017 Oct.

PMID:
28768669
8.

Summary of the Chronic Obstructive Pulmonary Disease Clinical Practice Guideline Revised in 2014 by the Korean Academy of Tuberculosis and Respiratory Disease.

Yoon HK, Park YB, Rhee CK, Lee JH, Oh YM; Committee of the Korean COPD Guideline 2014.

Tuberc Respir Dis (Seoul). 2017 Jul;80(3):230-240. doi: 10.4046/trd.2017.80.3.230. Epub 2017 Jul 3. Review.

9.

Microbiome in chronic obstructive pulmonary disease.

Monsó E.

Ann Transl Med. 2017 Jun;5(12):251. doi: 10.21037/atm.2017.04.20. Review.

10.

Oropharyngeal and Sputum Microbiomes Are Similar Following Exacerbation of Chronic Obstructive Pulmonary Disease.

Liu HY, Zhang SY, Yang WY, Su XF, He Y, Zhou HW, Su J.

Front Microbiol. 2017 Jun 22;8:1163. doi: 10.3389/fmicb.2017.01163. eCollection 2017.

11.

Serum levels of IGFBP7 are elevated during acute exacerbation in COPD patients.

Ruan W, Wu M, Shi L, Li F, Dong L, Qiu Y, Wu X, Ying K.

Int J Chron Obstruct Pulmon Dis. 2017 Jun 19;12:1775-1780. doi: 10.2147/COPD.S132652. eCollection 2017.

12.

A Cation-binding Surface Protein as a Vaccine Antigen to Prevent Moraxella catarrhalis Otitis Media and Infections in Chronic Obstructive Pulmonary Disease.

Murphy TF, Brauer AL, Johnson A, Wilding GE, Koszelak-Rosenblum M, Malkowski MG.

Clin Vaccine Immunol. 2017 Jun 28. pii: CVI.00130-17. doi: 10.1128/CVI.00130-17. [Epub ahead of print]

PMID:
28659326
13.

Chronic Respiratory Infection in Patients with Chronic Obstructive Pulmonary Disease: What Is the Role of Antibiotics?

Miravitlles M, Anzueto A.

Int J Mol Sci. 2017 Jun 23;18(7). pii: E1344. doi: 10.3390/ijms18071344. Review.

14.

Is Methicillin-Resistant Staphylococcus Aureus Colonization Associated with Worse Outcomes in COPD Hospitalizations?

Narewski ER, Kim V, Marchetti N, Jacobs MR, Criner GJ.

Chronic Obstr Pulm Dis. 2015;2(3):252-258. doi: 10.15326/jcopdf.2.3.2014.0147.

15.

Serum inflammatory biomarkers and clinical outcomes of COPD exacerbation caused by different pathogens.

Kawamatawong T, Apiwattanaporn A, Siricharoonwong W.

Int J Chron Obstruct Pulmon Dis. 2017 May 31;12:1625-1630. doi: 10.2147/COPD.S132132. eCollection 2017.

16.

Bronchiectasis in COPD patients: more than a comorbidity?

Martinez-Garcia MA, Miravitlles M.

Int J Chron Obstruct Pulmon Dis. 2017 May 11;12:1401-1411. doi: 10.2147/COPD.S132961. eCollection 2017.

17.

Cigarette smoke inhibits LPS-induced FABP5 expression by preventing c-Jun binding to the FABP5 promoter.

Rao D, Perraud AL, Schmitz C, Gally F.

PLoS One. 2017 May 18;12(5):e0178021. doi: 10.1371/journal.pone.0178021. eCollection 2017.

18.

Human β-defensin-2 production upon viral and bacterial co-infection is attenuated in COPD.

Arnason JW, Murphy JC, Kooi C, Wiehler S, Traves SL, Shelfoon C, Maciejewski B, Dumonceaux CJ, Lewenza WS, Proud D, Leigh R.

PLoS One. 2017 May 10;12(5):e0175963. doi: 10.1371/journal.pone.0175963. eCollection 2017.

19.

Investigating the role of pentraxin 3 as a biomarker for bacterial infection in subjects with COPD.

Thulborn SJ, Dilpazir M, Haldar K, Mistry V, Brightling CE, Barer MR, Bafadhel M.

Int J Chron Obstruct Pulmon Dis. 2017 Apr 18;12:1199-1205. doi: 10.2147/COPD.S123528. eCollection 2017.

20.

Insights on persistent airway infection by non-typeable Haemophilus influenzae in chronic obstructive pulmonary disease.

Ahearn CP, Gallo MC, Murphy TF.

Pathog Dis. 2017 Jun 1;75(4). doi: 10.1093/femspd/ftx042.

PMID:
28449098

Supplemental Content

Support Center